Mark A Schroeder
Overview
Explore the profile of Mark A Schroeder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
4094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abboud R, Schroeder M, Rettig M, Jayasinghe R, Gao F, Eisele J, et al.
Blood
. 2024 Nov;
PMID: 39576962
Haploidentical hematopoietic cell transplantation (haplo-HCT) is an increasingly used treatment for hematologic malignancies. Although post-transplant cyclophosphamide (PtCy) has improved graft vs. host disease (GvHD) prophylaxis in haplo-HCT, patients continue to...
2.
A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
Goldsmith S, Slade M, Fiala M, Harding M, Crees Z, Schroeder M, et al.
Ann Hematol
. 2024 Sep;
103(11):4557-4565.
PMID: 39227452
Introduction: Patients with triple-class refractory (TCR) multiple myeloma (MM) often need cytoreductive chemotherapy for rapid disease control. Bendamustine is an outpatient-administered, bifunctional alkylator and isatuximab is an anti-CD38 monoclonal antibody...
3.
Ha Y, Rajani K, Riviere-Cazaux C, Rahman M, Olson I, Gharibi Loron A, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123433
Aberrant metabolism is a hallmark of malignancies including gliomas. Intracranial microdialysis enables the longitudinal collection of extracellular metabolites within CNS tissues including gliomas and can be leveraged to evaluate changes...
4.
Kumar S, Callander N, Adekola K, Anderson Jr L, Baljevic M, Baz R, et al.
J Natl Compr Canc Netw
. 2024 Jan;
22(1D):e240001.
PMID: 38244272
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment,...
5.
Liu L, Wang M, Grandhi N, Schroeder M, Thomas T, Vargo K, et al.
J Hematol Oncol
. 2024 Jan;
17(1):3.
PMID: 38191467
Herbicide and pesticide exposure [e.g., agent orange (AO)] is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However, it is unclear whether TCDD/AO...
6.
Kumar S, Callander N, Adekola K, Anderson Jr L, Baljevic M, Baz R, et al.
J Natl Compr Canc Netw
. 2023 Dec;
21(12):1281-1301.
PMID: 38081133
The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR...
7.
Liu L, Wang M, Grandhi N, Schroeder M, Thomas T, Vargo K, et al.
Res Sq
. 2023 Oct;
PMID: 37886452
Background: Herbicide and pesticide exposure (e.g., agent orange [AO]) is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Monoclonal gammopathy of undetermined significance...
8.
Slade M, Fiala M, Kirchmeyer M, King J, Gao F, Schroeder M, et al.
Transplant Cell Ther
. 2023 Sep;
29(12):764.e1-764.e7.
PMID: 37741459
Second autologous hematopoietic cell transplantation (AHCT2) is a useful therapeutic modality for fit patients with multiple myeloma who have durable remission after upfront AHCT. Retrospective studies have suggested a significant...
9.
Xu Z, Choi J, Cooper M, King J, Fiala M, Liu J, et al.
Transplant Cell Ther
. 2023 Aug;
29(11):699.e1-699.e9.
PMID: 37597685
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (allo-HCT). The hypomethylating agent azacitidine (AZA) has been shown to be effective in preclinical and clinical studies for...
10.
Loncharich A, Fiala M, Slade M, Vickroy A, Kavanaugh M, Wilson C, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Aug;
23(11):825-828.
PMID: 37543510
Background: Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher...